返回Google圖書搜尋

Efficacy And Safety Of 1-Day Versus 3-Day Dexamethasone For The Prophylaxis Of Chemotherapy-Induced Nausea And Vomiting

其他書名	A Systematic Review And Meta-Analysis Of Randomized Controlled Trials
出版	Morressier, 2017
URL	http://books.google.com.hk/books?id=IimxzQEACAAJ&hl=&source=gbs_api

註釋IntroductionDexamethasone is typically administered for multiple days after the start of chemotherapy to prevent delayed chemotherapy-induced nausea and vomiting (CINV). Frequent administration of corticosteroids has been associated with problematic side effects. Reducing the dose and frequency of corticosteroids administered during chemotherapy treatment may be beneficial in reducing the side effects experienced by patients, as long as it is possible to maintain its efficacy in the prophylaxis of CINV. The aim of this review/meta-analysis is to compare the safety and efficacy of multi-day versus 1-day regimen of dexamethasoneMethodsA literature search was carried out in Ovid MEDLINE, Embase and Cochrane Central Register of Controlled Trials. The primary endpoints were proportion of patients achieving complete response and complete control. Secondary endpoints were percentage of patients who experienced no nausea, no emesis, no use of rescue medication, no adverse events, no constipation, no headache, and no fatigue/insomnia.ResultsSeven randomized controlled trials were included, and a total of 659 and 649 patients were randomized to receive 1-day and 3-day dexamethasone, respectively. The two treatments were equivalent in 16 of 17 endpoints.ConclusionsDespite the paucity of data in this setting, we find that 1-day dexamethasone therapy provides a similar efficacy and safety profile as a 3-day treatment. The similarities in efficacy and safety suggest that 1-day can be administered as an alternative to 3-day, supporting the latest American Society of Clinical Oncologyu2019s antiemetic guidelines suggesting 1-day instead of 3-day for some patients receiving moderately-emetogenic chemotherapy.